Search

Your search keyword '"Fiteni, Frédéric"' showing total 50 results
Start Over Author "Fiteni, Frédéric"
50 results on '"Fiteni, Frédéric"'

5. Clinical utility of ctDNA as a tool to detect triple-negative breast cancer relapses: The CUPCAKE trial.

Author

Bidard, Francois Clement, primary, Berger, Frederique, additional, Arnedos, Monica, additional, Mouret-Reynier, Marie-Ange, additional, Tredan, Olivier, additional, Sabatier, Renaud, additional, Jacot, William, additional, Massard, Vincent, additional, De La Motte Rouge, Thibault, additional, Gligorov, Joseph, additional, Teixeira, Luis, additional, Fiteni, Frédéric, additional, Grenier, Julien, additional, Dalenc, Florence, additional, Buvat, Irène, additional, Mechta-Grigoriou, Fatima, additional, and Kiavue, Nicolas, additional

Published
2024
Full Text
View/download PDF

16. 2022-RA-703-ESGO Primary and interval debulking surgery in advanced ovarian cancer: real-world clinical outcomes of patients in 1st line setting, analysis from the french national ESME-unicancer database

Author

Costaz, Hélène, primary, Boussere, Amal, additional, Thomas, Quentin Dominique, additional, Ray-Coquard, Isabelle, additional, Pomel, Christophe, additional, Gladieff, Laurence, additional, Marchal, Frédéric Marchal, additional, Laas, Enora, additional, Rouzier, Roman, additional, Sabatier, Renaud, additional, Floquet, Anne, additional, Rouge, Thibault de la Motte, additional, Pautier, Patricia, additional, Leblanc, Eric, additional, Barranger, Emmanuel, additional, Petit, Thierry, additional, Fiteni, Frédéric, additional, Colombo, Pierre-Emmanuel, additional, Martin, Anne-Laure Martin, additional, and Classe, Jean-Marc, additional

Published
2022
Full Text
View/download PDF

17. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort

Author

Thomas, Quentin Dominique, primary, Boussere, Amal, additional, Classe, Jean-Marc, additional, Pomel, Christophe, additional, Costaz, Hélène, additional, Rodrigues, Manuel, additional, Ray-Coquard, Isabelle, additional, Gladieff, Laurence, additional, Rouzier, Roman, additional, Rouge, Thibault De La Motte, additional, Gouy, Sébastien, additional, Barranger, Emmanuel, additional, Sabatier, Renaud, additional, Floquet, Anne, additional, Marchal, Frédéric, additional, Guillemet, Cécile, additional, Polivka, Valentine, additional, Martin, Anne-Laure, additional, Colombo, Pierre-Emmanuel, additional, and Fiteni, Frédéric, additional

Published
2022
Full Text
View/download PDF

20. Pharmacokinetic Variability Drives Palbociclib-Induced Neutropenia in Metastatic Breast Cancer Patients: Drug–Drug Interactions Are the Usual Suspects

Author

Leenhardt, Fanny, primary, Fiteni, Frédéric, additional, Gauthier, Ludovic, additional, Alexandre, Marie, additional, Guiu, Séverine, additional, Firmin, Nelly, additional, Pouderoux, Stéphane, additional, Viala, Marie, additional, Lossaint, Gerald, additional, Gautier, Chloé, additional, Mollevi, Caroline, additional, Gracia, Matthieu, additional, Gongora, Celine, additional, Mbatchi, Litaty, additional, Evrard, Alexandre, additional, and Jacot, William, additional

Published
2022
Full Text
View/download PDF

21. Abstract P5-13-23: Pharmacokinetic determinants of palbociclib hematological toxicity

Author

Leenhardt, Fanny, primary, Fiteni, Frédéric, additional, Gauthier, Ludovic, additional, Alexandre, Marie, additional, Guiu, Séverine, additional, Firmin, Nelly, additional, Pouderoux, Stéphane, additional, Gautier, Chloé, additional, Lossaint, Gerald, additional, Payen, Alexandre, additional, Gongora, Celine, additional, Mbatchi, Litaty, additional, Evrard, Alexandre, additional, and Jacot, William, additional

Published
2022
Full Text
View/download PDF

23. INMCancer : Base de données ouverte des publications d’études interventionnelles en prévention et soin des cancers sur les interventions non médicamenteuses (INM): Revues avant publié une étude interventionnelle sur une INM Publications

Author

Ninot, Gregory, Boulze-Launay, Isabelle, Guerdoux, Estelle, Laffray, Sophie, Rapior, Sylvie, Stoebner-Delbarre, Anne, Senesse, Pierre, Torres, Sacha, Fiteni, Frédéric, Dynamique des capacités humaines et des conduites de santé (EPSYLON), Université de Montpellier (UM)-Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 1 (UM1), Centre d’Ecologie Fonctionnelle et Evolutive (CEFE), Université Paul-Valéry - Montpellier 3 (UPVM)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Univ Montpellier, Université Montpellier 1 (UM1)-Université Paul-Valéry - Montpellier 3 (UPVM)-Université de Montpellier (UM), Université Paul-Valéry - Montpellier 3 (UPVM)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)-Institut Agro - Montpellier SupAgro, and Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)

Subjects
[SDV]Life Sciences [q-bio], [SDE]Environmental Sciences, [CHIM]Chemical Sciences
Abstract

Connaître les publications d’études comparatives sur les INM en prévention et soin des cancers; International audience; Les professionnels de la lutte contre le cancer recourent de plus en plus aux interventions non médicamenteuses (INM). Elles se distinguent des médecines alternatives, des pratiques socioculturelles et des campagnes de santé publique (Ninot, 2019). Ces méthodes ciblées et personnalisées s'intègrent dans le parcours de soin oncologique. Elles sont fondées sur la science, et en particulier sur des études interventionnelles (Ninot, 2020). Elles visent à (1) atténuer les symptômes du cancer et de ses traitements (fatigue, anxiété, douleur…), (2) prévenir la survenue ou la récidive d'un cancer, (3) prévenir des comorbidités, (4) améliorer l'état général de santé et la qualité de vie, (5) et à augmenter la durée de vie sans perte de qualité de vie. De nombreux chercheurs constatent des difficultés à identifier les publications d'études interventionnelles sur les INM dans la littérature (HAS, 2011). Les principales bases de données mondiales sont spécialisées dans une approche disciplinaire (biomédicale pour Pubmed, psychologique pour PsyInfo…), alors que par essence les INM font appel à des mécanismes biopsychosociaux et des contenus associant plusieurs composants (techniques, ingrédients…). Par ailleurs, la transformation numérique de l'édition scientifique ces 10 dernières années a diversifié l'offre de publication d'articles (Open Journals, Archive Ouverte…) de telle manière que de nombreuses études et publications échappent aux bases de données classiques. Ce système inédit, dédié à la prévention des cancers et aux soins de support en oncologie, et spécifique aux INM, se nomme INMCancer.

Published
2020

24. INMCancer : Base de données ouverte des publications d’études interventionnelles en prévention et soin des cancers sur les interventions non médicamenteuses (INM)

Author

Ninot, Gregory, Boulze-Launay, Isabelle, Guerdoux, Estelle, Laffray, Sophie, Rapior, Sylvie, Stoebner-Delbarre, Anne, Senesse, Pierre, TORRES, Sacha, Fiteni, Frédéric, Dynamique des capacités humaines et des conduites de santé (EPSYLON), Université de Montpellier (UM)-Université Paul-Valéry - Montpellier 3 (UPVM)-Université Montpellier 1 (UM1), Centre d’Ecologie Fonctionnelle et Evolutive (CEFE), Université Paul-Valéry - Montpellier 3 (UPVM)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), and Univ Montpellier

Subjects
[SDV]Life Sciences [q-bio], [SDE]Environmental Sciences, [CHIM]Chemical Sciences
Abstract

Connaître les publications d’études comparatives sur les INM en prévention et soin des cancers; International audience; Les professionnels de la lutte contre le cancer recourent de plus en plus aux interventions non médicamenteuses (INM). Elles se distinguent des médecines alternatives, des pratiques socioculturelles et des campagnes de santé publique (Ninot, 2019). Ces méthodes ciblées et personnalisées s'intègrent dans le parcours de soin oncologique. Elles sont fondées sur la science, et en particulier sur des études interventionnelles (Ninot, 2020). Elles visent à (1) atténuer les symptômes du cancer et de ses traitements (fatigue, anxiété, douleur…), (2) prévenir la survenue ou la récidive d'un cancer, (3) prévenir des comorbidités, (4) améliorer l'état général de santé et la qualité de vie, (5) et à augmenter la durée de vie sans perte de qualité de vie. De nombreux chercheurs constatent des difficultés à identifier les publications d'études interventionnelles sur les INM dans la littérature (HAS, 2011). Les principales bases de données mondiales sont spécialisées dans une approche disciplinaire (biomédicale pour Pubmed, psychologique pour PsyInfo…), alors que par essence les INM font appel à des mécanismes biopsychosociaux et des contenus associant plusieurs composants (techniques, ingrédients…). Par ailleurs, la transformation numérique de l'édition scientifique ces 10 dernières années a diversifié l'offre de publication d'articles (Open Journals, Archive Ouverte…) de telle manière que de nombreuses études et publications échappent aux bases de données classiques. Ce système inédit, dédié à la prévention des cancers et aux soins de support en oncologie, et spécifique aux INM, se nomme INMCancer.

Published
2020

25. 47-Poster-Ninot-2020-INMCancer_Base de données ouverte des publications d’études interventionnelles en prévention et soin des cancers sur les interventions non médicamenteuses/Open database of publications of interventional studies in cancer prevention and care on non-pharmacological interventions

Author

Ninot, Grégory, LAUNAY, Isabelle BOULZE, Guerdoux, Estelle, Laffray, Sophie, Rapior, Sylvie, Stoebner-Delbarre, Anne, Senesse, Pierre, TORRES, Sacha, and FITENI, Frédéric

Published
2020
Full Text
View/download PDF

26. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Author

Lièvre, Astrid, primary, Turpin, Anthony, additional, Ray-Coquard, Isabelle, additional, Le Malicot, Karine, additional, Thariat, Juliette, additional, Ahle, Guido, additional, Neuzillet, Cindy, additional, Paoletti, Xavier, additional, Bouché, Olivier, additional, Aldabbagh, Kais, additional, Michel, Pierre, additional, Debieuvre, Didier, additional, Canellas, Anthony, additional, Wislez, Marie, additional, Laurent, Lucie, additional, Mabro, May, additional, Colle, Raphael, additional, Hardy-Bessard, Anne-Claire, additional, Mansi, Laura, additional, Colomba, Emeline, additional, Bourhis, Jean, additional, Gorphe, Philippe, additional, Pointreau, Yoann, additional, Idbaih, Ahmed, additional, Ursu, Renata, additional, Di Stefano, Anna Luisa, additional, Zalcman, Gérard, additional, Aparicio, Thomas, additional, Moulin, Solenne, additional, Leleu, Olivier, additional, Leparree, Sylvie, additional, Goasdoue, Henri, additional, Piprot, Christine, additional, Tourneur, Gerald, additional, Bayart, Vincent, additional, Lignier, Delphine, additional, Lachaier, Emma, additional, Khamari, Marwa, additional, Coutte, Alexandre, additional, Siembida, Nicolas, additional, Houessinon, Aline, additional, Regimbeau, Jean Marc, additional, Chauffert, Bruno, additional, Moreira, Aurélie, additional, Hautefeuille, Vincent, additional, Hee, Christine, additional, Boone, Mathieu, additional, Bihan, Céline, additional, Chive, Emilie, additional, Poulet-Potriquier, Stéphane, additional, Fahem, Rachida, additional, Luet, Dominique, additional, Roquin, Guillaume, additional, Vitellius, Carole, additional, Cornet-Trichereau, Nathanaëlle, additional, Caroli-Bosc, François-Xavier, additional, Thirot-Bidault, Anne, additional, Ropert, Stanislas, additional, Gachet - Masson, Julie, additional, Dehais, Mélanie, additional, L'helgoualc'h, Gwen-Ael, additional, Ali-Mahamadou, Ibrahim, additional, Talfi, Safia, additional, Belmont, Laure, additional, Kilendo, Dieudonné, additional, Benrezzak, Nasro, additional, Dubief, Emeline, additional, Conroy, Guillaume, additional, Delique, Laurence, additional, Basso, Maud, additional, Pons, Isabelle, additional, Salignon, Karine, additional, Villing, Anne-Laure, additional, Mougenot, Emmanuelle, additional, Porebski, Cassandra, additional, Guiatni, Asma, additional, Cloarec, Nicolas, additional, Mineur, Laurent, additional, Bouchaud, Marie, additional, David, Céleste, additional, Peytier, Annie, additional, Greletty, Thomas, additional, Audemar, Franck, additional, Vignes, Emanuelle, additional, Minne, Floriane, additional, Goldzak, Guillaume, additional, Huysman, Fabienne, additional, Hocine, Fayçal, additional, Lakkis, Zaher, additional, Meynard, Guillaume, additional, Almotlak, Hamadi, additional, Klajer, Elodie, additional, Sun, Xu-Shan, additional, Wasselin, Julie, additional, Catala, Pascale, additional, Mazuy, Claire, additional, Vandamme, Hélène, additional, Prevost, Jean-Briac, additional, Fadin, Aurélie, additional, Basson, Laurent, additional, Huguet, Jean-Baptiste, additional, Dos Santos, Emmanuelle, additional, Jany, Bérangère, additional, Saad, Alain, additional, Goutorbe, Frédéric, additional, Oziol, Eric, additional, Ramdani, Mohamed, additional, Kadiri, Ouafae, additional, Garbay, Delphine, additional, Huet, Clotilde, additional, Giroux Leprieur, Etienne, additional, Teng, Wen, additional, Monvoisin, Justine, additional, Arnaud Coffin, Patrick, additional, Roux, Sylvie, additional, Orfeuvre, Hubert, additional, Chagros, Mélanie, additional, Pillon, Didier, additional, Rassoul, Agathe, additional, Poureau, Pierre Guillaume, additional, Novello, Cécile, additional, Ducray, François, additional, Trouba, Cécile, additional, Bastit, Vianney, additional, Babin, Emmanuel, additional, Leon, Vincent, additional, Courtecuisse, Anne-Catherine, additional, Vambre, Julie, additional, Tack, Vincent, additional, Desauw, Christophe, additional, Meniai, Fatima, additional, Peres, Christina, additional, Esparcieux, Aurélie, additional, Perrier, Hervé, additional, Doux, Nathalie, additional, Kaphan, Régis, additional, Roques, Bertrand, additional, Rebischung, Christine, additional, Mille, Dominique, additional, Fernandes, Gaëlle, additional, Abdelli, Naceur, additional, Jousset, Natacha, additional, Combe, Pierre, additional, Jonveaux, Eric, additional, Dumont, Patrick, additional, Kanaan, Marc, additional, Berthelot Gras, Corinne, additional, Panis, Valérie, additional, Kaluzinski, Laure, additional, Venant-Valery, Marjolène, additional, Lam, You-Heng, additional, Vallee, Laura, additional, Riviere, Frédéric, additional, Durand, Muriel, additional, Benghadid, Dihya, additional, Villeneuve, Emilie, additional, Hentic Dhome, Olivia, additional, Bounouar, Zedjiga, additional, De Mestier, Louis, additional, Dubois, Jacqueline, additional, Eyriey, Magali, additional, Moreau, Lionel, additional, Baihas, Dib, additional, Aldabbagh, Kaïs, additional, Degriffolet, Dominique, additional, Sebbagh, Virginie, additional, Seghezzi, Jean-Christophe, additional, Lozach-Brugirard, Marion, additional, Mandrou, Julie, additional, Mavier, Loubna, additional, Hennetier, Florence, additional, Wagner, Jean-Philippe, additional, Carola, Elisabeth, additional, Chandirakumaran, Karthiga, additional, Loutski, Sandrine, additional, Cojean-Zelek, Isabelle, additional, Bouras, Amina, additional, Lacour, Sandrine, additional, Froura, Fahem, additional, Ben Nadji, Hadjer, additional, Cattelain, Sophie, additional, Darloy, Franck, additional, Jolimoy Boilleau, Geneviève, additional, Maissiat, Cyrielle, additional, Darut-Jouve, Ariane, additional, Lorgis, Véronique, additional, Charifi-Alaoui, Ikram, additional, Ghiringhelli, François, additional, Drouillard, Antoine, additional, Chaix, Marie, additional, Manfredi, Sylvain, additional, Lepage, Côme, additional, Gagnaire, Alice, additional, Latournerie, Marianne, additional, jourdan, Sofia, additional, Perrot, Nora, additional, folia, Mireille, additional, Minello, Anne, additional, Jouve, Jean-Louis, additional, Fery, Marielle, additional, Landau, Alain, additional, Evrard, Diane, additional, Valenza, Bruno, additional, Paitel, Jean-François, additional, Chablais, Laetitia, additional, Kreitmann, Thomas, additional, Lancry-Lecomte, Laurence, additional, Monard, Adrien, additional, Faugeras, Eve, additional, Boucheret, Paul, additional, Glommeau, Cécile, additional, Tchikladze, Christine, additional, Garnier Tixidre, Claire, additional, Long, Jérôme, additional, Zaidi, Manel, additional, Delabarre, Véronique, additional, Meyzenc, Juliette, additional, Ferrand, Loïc, additional, Moro-Sibilot, Denis, additional, Bouheret, Paul, additional, Leyronnas, Cécile, additional, Herve, Camille, additional, Thoor, Audrey, additional, Jacquet, Emanuelle, additional, Roth, Gaël, additional, Madapathage-Senanyake, Videsheka, additional, Chupeau, Peggy, additional, Bieber, Elsa, additional, Rosso, Maud, additional, Lepage, Isabelle, additional, Priou, Frank, additional, Laly, Margot, additional, Aprelon, Sylvie, additional, Sobolak, Natacha, additional, Homokos, Helen, additional, Watelle, Fabienne, additional, Pham-Becker, Alice, additional, Lauridant, Géraldine, additional, Dujardin, Charlotte, additional, Lenglin, Etienne, additional, Nienguet Tsota, Aimée, additional, Dominguez, Sophie, additional, Forestier, Alexandra, additional, Nouvel, Franck, additional, Lerooy, Justine, additional, Ratajczak, Céline, additional, Romano, Olivier, additional, Brzyski, Dorothéee, additional, Barriere, Aurélien, additional, Genet, Dominique, additional, Tisse, Julien, additional, Zasadny, Xavier, additional, Grelet, Adeline, additional, Hennion-Imbault, Amélie, additional, Haustraete, Eglantine, additional, Louafi, Samy, additional, Awad, Manal, additional, Zekri, Younes, additional, Cheneau, Caroline, additional, Leissen, Nolwen, additional, Egreteau, Joëlle, additional, Breant, Alexandra, additional, Sarabi, Matthieu, additional, Labonne, Stéphanie, additional, Forestier, Julien, additional, Leclercq, Céline, additional, Prunier-Bossion, Florence, additional, Ray Coquard, Isabelle, additional, Guillet, Marielle, additional, Theillaumas, Aurélie, additional, Prome, Emilie, additional, Walter, Thomas, additional, Philouze, Pierre, additional, Lawo, Melody, additional, De Talhouet, Solène, additional, Beuvelot, Johanne, additional, Molin, Yann, additional, Bellecoste Martin, Marie, additional, Saussereau, Maud, additional, Agnelli, Lauren, additional, Fakhry, Nicolas, additional, Laplace, Christophe, additional, Norguet Monnereau, Emmanuelle, additional, Boucard, Céline, additional, Djenad, Kahina, additional, Fontaine, Catherine, additional, Seitz, Jean-François, additional, Dahan, Laétitia, additional, Sigrand, Julie, additional, Duluc, Muriel, additional, Locher, Christophe, additional, Fleury, Marjory, additional, Brou Marie, Ange, additional, Berkane, Ramdane, additional, Poupblanc, Séverine, additional, Auby, Dominique, additional, Petran, Daniela, additional, Texereau, Patrick, additional, Guerineau, Elodie, additional, Andre, Morgan, additional, Mahjoubi, Linda, additional, Sarrazin, Fanny, additional, Jeanson, Sonia, additional, Gschwend, Anthony, additional, Birr, Virginie, additional, Fore, Mathieu, additional, Noirclerc, Monique, additional, Dahou, Sihem, additional, Spaeth, Dominique, additional, Lambotin, Mélanie, additional, Lelu, Thomas, additional, Linot, Benjamin, additional, Hugon, Nathalie, additional, Rousseau, Dominique, additional, Castanie, Hélène, additional, Lenne, Carole, additional, Lortholary, Alain, additional, Cessot, Anatole, additional, Merzoug, Messaouda, additional, Naudin, Cécile, additional, Vannetzel, Jean-Michel, additional, Aziz, Ghina, additional, Hadj Arab, Yacine, additional, Pernes, Stéphanie, additional, Roche-Lachaise, Isabelle, additional, Fiteni, Frédéric, additional, Yahiaoui, Hadjer, additional, Marel Lopez, Gwendoline, additional, Oddoz, Jeanne, additional, Peira, Fabienne, additional, Michel, Olivier, additional, Meunier, Jérôme, additional, Ouahrani, Brahim, additional, Roger, Antoine, additional, Branco, Sonia, additional, Nguyen, Van, additional, Gisselbrecht, Mathilde, additional, Hammad, Ghania, additional, Mordant, Pierre, additional, Stroksztejn, Magda, additional, Pocard, Marc, additional, Nlo Meyengue, Luc, additional, Sacco, Emmanuelle, additional, Simon Anne, Sophie, additional, Fabre-Guillevin, Elizabeth, additional, Slim, Marine, additional, Zaanan, Aziz, additional, Cadranel, Jacques, additional, Pluvy, Johan, additional, Ursu, Rénata, additional, Geraldo, Amyrath, additional, Lihi, Rime, additional, Vo, Maryline, additional, Brouk, Zohra, additional, Colle, Raphaël, additional, Bennamoun, Mostefa, additional, Lacan, Fabrice, additional, Louvet, Christophe, additional, Mebarki, Soraya, additional, Veyri, Marianne, additional, Paillaud, Elena, additional, Lucas, Christelle, additional, Dubreuil, Olivier, additional, Lyamani, Jamila, additional, Agguini, Hanane, additional, Soularue, Emilie, additional, Jourdaine, Clément, additional, Verillaud, Benjamin, additional, Herzine, Hakima, additional, Raymond, Eric, additional, Mathiot, Nathalie, additional, Palmieri, Lola Jade, additional, Epanya, Christian, additional, Taieb, Julien, additional, Bertrand, Eliane, additional, Goujon, Gaël, additional, Namour, Céline, additional, Gazeau, Benoit, additional, Zafirova, Biljana, additional, Mirghani, Haitham, additional, Belin, Catherine, additional, Belkhir, Kahina, additional, Gharib, Myriam, additional, Vozy, Aurore, additional, Amrane, Karim, additional, Spano, Jean-Philippe, additional, Wassermann, Johanna, additional, Feuvret, Loic, additional, Bachet, Jean-Baptiste, additional, Philonenko, Sara, additional, Guillot, Laetitia, additional, Zabbe, Marion, additional, Gibiat, Stéphanie, additional, Baylot, Camille, additional, Jouinot, Aude, additional, Leduc, Nicolas, additional, Vieillot, Sabine, additional, James, Laurie, additional, Ducerf, Camille, additional, Blanc, Jean-Frédéric, additional, Falandry Leger, Claire, additional, Wautot, Virginie, additional, Chauvenet, Marion, additional, Vincent, Aude, additional, Tougeron, David, additional, Goulvent, Sandrine, additional, Suc, Etienne, additional, Laurenty, Anne-Pascale, additional, Marquis, Eric, additional, Bonnaire, Margaux, additional, Dewolf, Maxime, additional, Brenet, Esteban, additional, Billard, Delphine, additional, Litre, Claude-Fabien, additional, Dumazet, Antoine, additional, Botsen, Damien, additional, Vazel, Marion, additional, Carlier, Claire, additional, Bonnerave, David, additional, Marchand-Crety, Charles, additional, Bouche, Olivier, additional, Fosse, Patricia, additional, Sefrioui, David, additional, Watson, Sarah, additional, Torche, Fatah, additional, Muron, Thierry, additional, Natur, Stéphane, additional, Desgrippes, Romain, additional, Bihel, Véronique, additional, Ferrand, François-Régis, additional, Leiterer, Caroline, additional, Lavole, Julie, additional, Moquet, Claire, additional, Pressoir, Nathalie, additional, Dziukala, Catherine, additional, Ligeza Poisson, Catherine, additional, Naji, Abdelhalim, additional, Williet, Nicolas, additional, Phelip, Jean-Marc, additional, Di Palma, Fabrice, additional, Kherrour Mehdi, Amina, additional, Langrand-Escure, Julien, additional, Fournel, Pierre, additional, Pigne, Grégoire, additional, Saban-Roche, Léa, additional, Magne, Nicolas, additional, Vassal, Cécile, additional, Jacquin, Jean-Philippe, additional, Ramirez, Carole, additional, Vallard, Alexis, additional, Collard, Olivier, additional, Rivoirard, Romain, additional, Graber, Ivan, additional, Trager Maury, Stéphanie, additional, Duboisset, Elodie, additional, Ayllon Ugarte, Jorge, additional, Rami, Dalilia, additional, Saler, Christine, additional, Reinbolt, Manon, additional, Le Fevre, Clara, additional, Ben Abdelghani, Meher, additional, Dourthe, Louis-Marie, additional, Perruisseau-Carrier, Joffrey, additional, Nguimpi-Tambou, Marlène, additional, Barret, Flavie, additional, Di Stefano Anna, Luisa, additional, Balthazard, Annie, additional, Vassord-Dang, Camille, additional, Le Marchand, Mathilde, additional, Vergniol, Julien, additional, Pripon, Iulia, additional, Daemaegdt, Axelle, additional, Latry, Vanessa, additional, Larrieu, Muna, additional, Landry, Gaëlle, additional, Touihri Maximin, Laetitia, additional, Del Piano, Francesco, additional, Barlet, Agnès, additional, Vernisse, Mylène, additional, Lafond, Sophie, additional, Genin, Charline, additional, Sibertin-Blanc, Camille, additional, Chabrillac, Emilien, additional, Gregoire, Caroline, additional, Vergez, Sébastien, additional, Panouille, Quentin, additional, Guimbaud, Rosine, additional, Richa, Floriane, additional, Lebellec, Loïc, additional, Gounin, Sophie, additional, Buiret, Guillaume, additional, Baudin, Marine, additional, Hamon, Hervé, additional, Deshorgue, Anne-Claire, additional, Barrascout, Eduardo, additional, Legrand, Stéphanie, additional, Houlze, Morgane, additional, Cambula, Linda, additional, Lopez, Anthony, additional, Fouquet, Guillaume, additional, Touabi, Kahina, additional, GermaIn, Adeline, additional, Godbert, Benoit, additional, Voivret, Florence, additional, Perrin, Julie, additional, Da Silva, Rosa, additional, and Bernichon, Emilie, additional

Published
2020
Full Text
View/download PDF

27. Patient-centered clinical endpoints in lung cancer trials

Author

Fiteni , Frédéric, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université de Franche-Comté, Virginie Westeel, Franck Bonnetain, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), and STAR, ABES

Subjects
Essais cliniques, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Critères de jugement centrés sur le patient, Méthodologie, Qualité de vie relative à la santé, Health-related quality of life, Methodology, [SDV.CAN]Life Sciences [q-bio]/Cancer, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Clinical trials, [SDV.CAN] Life Sciences [q-bio]/Cancer, Patient-centered clinical endpoint, Critères de jugement, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, Cancer du poumon, Endpoints, Lung cancer, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Overall survival (OS) is the gold standard endpoint in oncology clinical trials. Nevertheless, intermediate tumor-centered endpoints which are assessed earlier are more and more used as surrogate of OS. Health-related quality of life is an endpoint which assesses a direct benefit for the patient. We demonstrated that 32% of endpoints in advanced non-small-cell lung phase III clinical trials were not defined at all, 43% were not clearly defined and none ofthem has demonstrated its surrogacy on OS. We demonstrated the weakness and the heterogeneity of the measurement, analysis, and reporting of HRQoL in phase III advanced NSCLC trials. Precise and uniform recommendations are needed. We longitudinally compared HRQoL using tüne until definitive deterioration (TUDD) method in 451 patients aged 70-89 years with advanced NSCLC randomly assigned to receive a doublet of chemotherapy or a monochemotherapy. We demonstrated the benefit of the doublet chemotherapy in terms ofHRQoL. On a methodological point ofview TUDD method is feasible and provide clinically meaningful results. We proposed another approach which would be to combine intermediate endpoint• with HRQoL as co-primary endpoints. Finally, we demonstrated the additional prognostic value of HRQoL data at baseline to identify vulnerable subpopulations in elderly NSCLC patients., La Survie globale (SG) est le critère de jugement de référence dans les essais cliniques en oncologie mais les critères de jugement dit intennédiaires centrés sur la tumeur qui sont évalués plus précocement sont de plus en plus utilisés comme critères substitutifs de la survie globale La qualité de vie (QdV) constitue un critère de jugement pour évaluer un bénéfice clinique direct pour le patient. Nos résultats ont montré que 32% des critères de jugement dans les essais de phase III de CBNPC avancés étaient pas du tout définis et seulement 43% était clairement défini et qu'aucun critère intermédiaire n'a démontré sa substitutivité sur la SG. Nous avons montré que la mesure, l'analyse et le report des données de QdV étaient hétérogènes entre les essais de phase III de CBNPC avancés d'où la nécessité de recommandations. Nous avons comparé longitudinalement la QdV chez 451 patients âgés de 70-89 ans atteints de CBNPC avancés randomisés entre une bichimiothérapie et une monochimiothérapie selon la technique du temps jusqu'à détérioration définitive (TJD) d'un score de QdV. Cette étude a montré : sur le plan clinique, le bénéfice du doublet de chimiothérapie pour les patients est renforcé par les données de QdV; sur le plan méthodologique: le TJD est une technique d'analyse faisable dans les essais de phase III de CBNPC et fournit des résultats faciles d'interprétation. Nous avons proposé l'utilisation de co-critères de jugement principaux associant QdV et critère centré sur la tumeur. Enfin, nous avons démontré la valeur pronostique de la dimension santé globale de QdV à baseline du questionnaire sur la SG chez les patients âgés atteints de CBNPC avancés.

Published
2016

29. Surrogate endpoints for overall survival in lung cancer trials: a review.

Author

Fiteni, Frédéric, Westeel, Virginie, Bonnetain, Franck, and Fiteni, Frédéric

Subjects
LUNG cancer treatment, TREATMENT of lung tumors, BIOLOGICAL assay, CLINICAL trials, COMBINED modality therapy, LUNG cancer, LUNG tumors, PROGNOSIS, SURVIVAL, TREATMENT effectiveness
Abstract

Introduction: Intermediate endpoints are often used as primary endpoints instead of overall survival (OS) in lung cancer trials but they are not systematically validated as surrogate endpoints for OS. Areas covered: The aim of the study was to review the studies which assessed potential surrogate endpoints for OS in lung cancer trials. Expert commentary: Twenty studies were identified. In operable non-small cell lung cancer (NSCLC) (adjuvant trials) and locally advanced NSCLC (radiotherapy trials), one individual-patient data meta-analysis found a high correlation of disease-free survival (DFS) and progression-free survival (PFS) with OS at patient and trial level. In trials of adjuvant chemotherapy, correlation between disease-free survival DFS and OS were 0.83 at the individual level (95% CI 0.83–0.83) and 0.92 at trial level (95% CI 0.88–0.95). In locally advanced disease, correlation between PFS and OS was 0.77 to 0.85 at the individual level, and 0.89 to 0.97 at trial level. This study provides a ‘proof’ of the surrogacy of PFS and DFS on OS according to the IQWiG framework and the surrogacy of PFS and DFS on OS was classified level 2 according to Fleming hierarchy. In all the other setting, no endpoint was judged to be valid surrogate for OS. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

30. Time-to-event endpoints in operable non-small-cell lung cancer randomized clinical trials.

Author

Fiteni, Frédéric, Paillard, Marie-Justine, Westeel, Virginie, Bonnetain, Franck, and Fiteni, Frédéric

Subjects
BIOLOGICAL assay, CLINICAL trials, LUNG cancer, LUNG tumors, MEDICAL protocols, MULTIVARIATE analysis, TIME, KAPLAN-Meier estimator, STANDARDS
Abstract

Introduction: No guideline for time-to-event endpoints (TTEE) definitions in lung cancer trials exists. Areas covered: The aim of the study was to evaluate the reporting of TTEE in operable non-small-cell lung cancer randomized clinical trials. Expert commentary: Sixty-two TTEE were recorded. In the Methods section, using four key points to define TTEE we observed that the ‘starting point’, ‘events’, ‘information on censoring’, ‘assessment of events’ were clearly defined for 43 (69.4%), 34 (54.8%), 6 (9.7%), 33 (53.2%) endpoints respectively. In the results section, using five key points, we observed that the ‘Kaplan-Meier estimation’, ‘estimation of effect size’, ‘precision (confidence interval)’, ‘number of events’, ‘number of patients at risk’, ‘multivariate analysis’ were clearly identified for 46 (74.2%), 31 (50%), 30 (48.4%), 37 (59.7%), 28 (45.2%), and 17 (27.4%) endpoints, respectively. A majority of articles failed to provide a complete reporting of TTEE. Guidelines for TTEE is warranted. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

34. Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma

Author

Fiteni, Frédéric, primary, Paget‐Bailly, Sophie, additional, Messager, Mathieu, additional, N'Guyen, Thierry, additional, Lakkis, Zaher, additional, Mathieu, Pierre, additional, Lamfichekh, Najib, additional, Picard, Alain, additional, Benzidane, Bilell, additional, Cléau, Denis, additional, Bonnetain, Franck, additional, Borg, Christophe, additional, Mariette, Christophe, additional, and Kim, Stefano, additional

Published
2016
Full Text
View/download PDF

35. Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy

Author

Fiteni, Frédéric, primary, Anota, Amélie, additional, Bonnetain, Franck, additional, Oster, Jean-Philippe, additional, Pichon, Eric, additional, Wislez, Marie, additional, Dauba, Jérôme, additional, Debieuvre, Didier, additional, Souquet, Pierre-Jean, additional, Bigay-Game, Laurence, additional, Molinier, Olivier, additional, Dansin, Eric, additional, Poudenx, Michel, additional, Milleron, Bernard, additional, Morin, Franck, additional, Zalcman, Gérard, additional, Quoix, Elisabeth, additional, and Westeel, Virginie, additional

Published
2016
Full Text
View/download PDF

38. Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients

Author

Fiteni, Frédéric, primary, Vernerey, Dewi, additional, Bonnetain, Franck, additional, Vaylet, Fabien, additional, Sennélart, Hélène, additional, Trédaniel, Jean, additional, Moro-Sibilot, Denis, additional, Herman, Dominique, additional, Laizé, Hélène, additional, Masson, Philippe, additional, Derollez, Marc, additional, Clément-Duchêne, Christelle, additional, Milleron, Bernard, additional, Morin, Franck, additional, Zalcman, Gérard, additional, Quoix, Elisabeth, additional, and Westeel, Virginie, additional

Published
2016
Full Text
View/download PDF

41. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy

Author

Fiteni, Frédéric, primary, Jary, Marine, additional, Monnien, Franck, additional, Nguyen, Thierry, additional, Beohou, Eric, additional, Demarchi, Martin, additional, Dobi, Erion, additional, Fein, Francine, additional, Cleau, Denis, additional, Fratté, Serge, additional, Nerich, Virginie, additional, Bonnetain, Franck, additional, Pivot, Xavier, additional, Borg, Christophe, additional, and Kim, Stefano, additional

Published
2014
Full Text
View/download PDF

43. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis

Author

Nerich, Virginie, primary, Chelly, Jennifer, additional, Montcuquet, Philippe, additional, Chaigneau, Loïc, additional, Villanueva, Cristian, additional, Fiteni, Frédéric, additional, Meneveau, Nathalie, additional, Perrin, Sophie, additional, Voidey, Aline, additional, Monnot, Tess, additional, Pivot, Xavier, additional, and Limat, Samuel, additional

Published
2013
Full Text
View/download PDF

44. First-line trastuzumab plus taxane-based chemotherapy for metastatic breast cancer: Cost-minimization analysis.

Author

Nerich, Virginie, Chelly, Jennifer, Montcuquet, Philippe, Chaigneau, Loïc, Villanueva, Cristian, Fiteni, Frédéric, Meneveau, Nathalie, Perrin, Sophie, Voidey, Aline, Monnot, Tess, Pivot, Xavier, and Limat, Samuel

Subjects
HYDROCARBONS, TRASTUZUMAB, BREAST tumors, CANCER chemotherapy, CHI-squared test, COST effectiveness, FISHER exact test, LONGITUDINAL method, MEDICAL care costs, METASTASIS, NONPARAMETRIC statistics, HEALTH outcome assessment, SURVIVAL analysis (Biometry), TREATMENT effectiveness, RETROSPECTIVE studies, DATA analysis software, DESCRIPTIVE statistics, MANN Whitney U Test, THERAPEUTICS
Abstract

Aim: To carry out a cost-minimization analysis including a comparison of the costs arising from first-line treatment by trastuzumab plus docetaxel versus trastuzumab plus paclitaxel in patients with metastatic breast cancer. Methods: All consecutive patients with human epidermal growth receptor 2-postive metastatic breast cancer who were treated at Besanc¸on University Hospital and Saint Vincent private hospital between 2001 and 2010 by first-line therapy containing trastuzumab plus taxane were retrospectively studied. Economic analysis took into account costs related to drugs, hospitalization, and healthcare travel. Results: Progression-free survival difference between the two treatments was not significant (p¼0.65). First-line treatment by trastuzumab plus taxane was estimated at approximately E68,000 (p¼0.74). The drug costs represented around 70–75% of the total cost, mainly related to the use of trastuzumab. Conclusion: Our economic analysis shows that although the costs of the two trastuzumab plus taxane regimens are similar, they may contribute to the on-going debate about the availability and use of innovative chemotherapy drugs, in particular in human epidermal growth factor receptor 2-positive metastatic breast cancer with new therapies such as trastuzumab-DM1 and pertuzumab. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

49. Enterocolitis in Patients with Cancer Treated with Docetaxel.

Author

Fiteni F, Paillard MJ, Orillard E, Lefebvre L, Nadjafizadeh S, Selmani Z, Benhamida S, Roland A, Baumann A, Vienot A, Houédé N, and Pivot X

Subjects
Adult, Aged, Aged, 80 and over, Docetaxel, Dose-Response Relationship, Drug, Female, Humans, Incidence, Male, Middle Aged, Nausea chemically induced, Nausea epidemiology, Neutropenia chemically induced, Neutropenia epidemiology, Retrospective Studies, Taxoids administration & dosage, Vomiting chemically induced, Vomiting epidemiology, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Enterocolitis chemically induced, Enterocolitis epidemiology, Neoplasms drug therapy, Neoplasms epidemiology, Taxoids adverse effects
Abstract

Background: Enterocolitis is a rare, but serious gastrointestinal complication associated with docetaxel-based chemotherapy in patients with cancer. The incidence, clinical presentation and outcome of enterocolitis in patients with cancer treated with docetaxel-based chemotherapy was assessed in this study Patients and Methods: All patients treated with docetaxel for cancer between January 2010 and December 2014 at the University Hospital of Besançon were identified and their medical records reviewed., Results: During this period, 1,227 patients received docetaxel chemotherapy and gastrointestinal events occurred in 381 (31.1%) patients. In multivariate analysis, a higher risk of gastrointestinal events was associated with a higher dose of docetaxel (≥75 mg/m 2 ) (odds ratio(OR)=46.2; 95% confidence interval(CI)=5.4-397.0, p=0.0005) and the first cycle of docetaxel (OR=4.2; 95% CI=1.8-10.1, p=0.001). Among the 381 patients with gastrointestinal events, grade 3/4 neutropenia, diarrhea, febrile neutropenia, mucositis, nausea/vomiting, and rectal bleeding were diagnosed in 65 (17.1%), 51 (13.4%), 37 (9.7%); 12 (3.1%), seven (1.8%) and three (0.8%) patients, respectively; 54 patients (14.2%) were hospitalized. Computed tomographic scan was performed for 39 patients (10.2%). Twenty-seven patients presented radiological signs of enterocolitis. Three deaths (0.8%) related to enterocolitis were recorded. Docetaxel was resumed in 261 patients (68.5%) and the dose was reduced in 89 patients (23.4%). Docetaxel was discontinued in 120 patients (31.5%)., Conclusion: Gastrointestinal events in patients treated with docetaxel may be a potential sign of fatal enterocolitis and require particular attention. Dose reduction at the first cycle may reduce the risk of such events., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)

Published
2018
Full Text
View/download PDF

50. [Health-related quality of life in phase III cancer clinical trials: from questionnaire administration to statistical analysis].

Author

Fiteni F, Anota A, Westeel V, and Bonnetain F

Subjects
Humans, Linear Models, Patient Outcome Assessment, Research Design, Survival Analysis, Clinical Trials, Phase III as Topic, Health Status, Neoplasms therapy, Quality of Life, Surveys and Questionnaires
Abstract

Endpoints refer to clinical and biological measurements that assess efficacy of therapeutic strategies. As the American Society of Clinical Oncology states, active treatment in cancer is generally undertaken with the goal of providing improved quantity and/or quality of patient survival. Health-related quality of life (HRQoL) reflects the patient-perceived evaluation of one's health, including physical, emotional, and social dimensions as well as symptoms due to disease or treatment. HRQoL is recognized as a component endpoint for cancer therapy approvals by the American Society of Clinical Oncology and the FDA. Many self-completion HRQoL questionnaires have been developed and validated. Two main statistical methods have been developed to longitudinally analyze HRQoL. The first is the linear mixed model for repeated measure (LMM). The second is a survival approach, which estimates the time to HRQoL deterioration. However, there is no guideline for methods of analyzing and reporting longitudinal changes in HRQoL scores. Moreover, HRQoL could also be combined with other endpoints like progression-free survival as co-primary endpoint, but the use of co-primary endpoints in cancer clinical trials is a new approach and methodological researches must be pursued to promote such designs., (Copyright © 2015 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results